Overview

Surveillance and Treatment of Prisoners With Hepatitis C

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess how feasible it is to treat and prevent the transmission of Hepatitis C in the prison setting to achieve substantial reductions in the incidence and prevalence of Hepatitis C. It is hypothesised that a rapid scale-up of Hepatitis C Virus (HCV) treatment with interferon-free Direct Acting Anti-virals (DAAs) in prison inmates will achieve a >50% reduction in the incidence of HCV infection over a two year period in the prison setting.
Phase:
Phase 4
Details
Lead Sponsor:
Kirby Institute
Treatments:
Sofosbuvir
Velpatasvir